Bridgewater Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.38M Sell
9,702
-101
-1% -$21.7K 0.13% 81
2026
Q1
$2.04M Sell
9,803
-299
-3% -$66.3K 0.12% 85
2025
Q4
$2.18M Sell
10,102
-143
-1% -$32.6K 0.14% 79
2025
Q3
$2.24M Buy
10,245
+201
+2% +$40.9K 0.16% 75
2025
Q2
$1.92M Buy
10,044
+17
+0.2% +$3.16K 0.15% 80
2025
Q1
$1.94M Buy
+10,027
New +$1.95M 0.17% 75
2022
Q3
Sell
-3,011
Closed -$461K 127
2022
Q2
$461K Sell
3,011
-204
-6% -$31.2K 0.1% 143
2022
Q1
$521K Buy
3,215
+675
+27% +$98.1K 0.13% 138
2021
Q4
$344K Buy
2,540
+47
+2% +$5.55K 0.08% 177
2021
Q3
$269K Buy
2,493
+102
+4% +$11.7K 0.07% 200
2021
Q2
$269K Buy
+2,391
New +$269K 0.09% 195

Other funds holding ABBV

Bridgewater Advisors's ABBV Position: Q2 2026 in Review

Bridgewater Advisors reduced its AbbVie (ABBV) stake by 1% in Q2 2026, selling an estimated $21.7K and leaving 9,702 shares worth $2.38M. The position accounts for 0.13% of the portfolio, ranked #81.

Bridgewater Advisors first reported a position in ABBV in Q2 2021 and has held it in 11 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Bridgewater Advisors held 9,702 shares of AbbVie worth $2.38M as of Q2 2026.
  • Bridgewater Advisors sold 101 AbbVie shares in Q2 2026, an estimated $21.7K.
  • AbbVie made up 0.13% of Bridgewater Advisors's portfolio in Q2 2026, its #81 holding.
  • Bridgewater Advisors first reported a position in AbbVie in Q2 2021 and has held it in 11 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bridgewater Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.